Biotelemetry
BEATBiotelemetry in brief
Biotelemetry is a listed company in the Healthcare sector, based in Pennsylvania, USA. Its market value was $34 M on 30 October 2026, which makes it the 22,587th largest listed company in the world and the 3,998th largest in the USA on this site. It employs about 1,500 people. Its shares trade under the symbol BEAT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Biotelemetry
BioTelemetry is the Mobile and Wireless Medical Technology Industry. It has focus on the delivery of health information to save and improve lives while reducing the cost of care. The Company provides cardiac and mobile blood glucose monitoring, centralized medical imaging and original equipment manufacturing serving the healthcare and clinical research sectors. The headquarters is in USA.
Biotelemetry timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 November 2021; shares registered for exchange trading on 10 November 2021.
Events of Biotelemetry from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,717 (Jan 2020) · #1,506 (Jan 2021) · #5,237 (Jan 2022) · #4,992 (Dec 2022) · #4,418 (Jul 2023) · #3,947 (Jan 2024) · #2,115 (Mar 2026) · #3,883 (Aug 2026) · #4,011 (Oct 2026) · #4,001 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 13.1×
- Free cash flow yield
- -42.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -808.5%
- Liabilities / assets
- 55.5%
- Profit per employee
- $-14 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-21M | $-21M | — |
| Dec 2024 | — | — | $-20M | $-19M | — |
| Dec 2023 | — | — | $-15M | $-15M | — |
| Dec 2022 | — | — | $-13M | $-13M | — |
| Dec 2021 | — | — | $-2M | $-4M | — |
| Dec 2020 | — | — | $-1M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | $1M | $-15M | $-0.62 | — |
| Dec 2024 | $-14M | $0M | $-15M | $-0.73 | — |
| Dec 2023 | $-12M | $0M | $-12M | $-0.72 | — |
| Dec 2022 | $-10M | $0M | $-10M | $-1.59 | — |
| Dec 2021 | $-3M | — | — | $-1.03 | — |
| Dec 2020 | $-1M | — | — | $-0.29 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Aug 14, 20268-KCurrent reportMaterial agreement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-K/ACurrent report (amended)Directors or officers changed
- Aug 3, 20268-KCurrent reportShareholder vote
- Jul 2, 20268-KCurrent reportListing notice
- Jun 24, 20268-KCurrent reportDirectors or officers changed · Other events
- Jun 22, 20268-KCurrent reportDirectors or officers changed
- Jun 18, 2026DEF 14AProxy statement
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 16, 20268-KCurrent reportMaterial agreement · Other events
- Mar 12, 202610-KAnnual report · period to Dec 2025
Official filings of Biotelemetry with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-21 M
- Net income
- $-21 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $6 M
- Total liabilities
- $3 M
- Total equity
- $3 M
As of December-2025
Top 39 institutional investors in Biotelemetry#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2,137,512 | 0 (0.00%) | 3.38% | $1 M | Nov 13, 2026 |
| 2 | BlackRock, Inc. | 980,669 | -7,168 (-0.73%) | 1.55% | $0 M | Nov 13, 2026 |
| 3 | Corsair Capital Management, L.P. | 662,500 | -250,000 (-27.40%) | 1.05% | $0 M | Nov 16, 2026 |
| 4 | Bleichroeder LP | 625,000 | 0 (0.00%) | 0.99% | $0 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 480,465 | +1,079 (+0.23%) | 0.76% | $0 M | Nov 6, 2026 |
| 6 | Sigma Planning Corp | 387,200 | +139,500 (+56.32%) | 0.61% | $0 M | Oct 23, 2026 |
| 7 | Smith Salley Wealth Management | 367,647 | 0 (0.00%) | 0.58% | $0 M | Nov 3, 2026 |
| 8 | O'shaughnessy Asset Management, LLC | 280,161 | +71,970 (+34.57%) | 0.44% | $0 M | Nov 12, 2026 |
| 9 | Ritholtz Wealth Management | 280,161 | +71,970 (+34.57%) | 0.44% | $0 M | Nov 5, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 274,818 | 0 (0.00%) | 0.43% | $0 M | Nov 13, 2026 |
| 11 | Beacon Pointe Advisors, LLC | 247,058 | 0 (0.00%) | 0.39% | $0 M | Nov 16, 2026 |
| 12 | UBS Group AG | 229,107 | -69,810 (-23.35%) | 0.36% | $0 M | Nov 10, 2026 |
| 13 | Kestra Private Wealth Services, LLC | 170,439 | -3,000 (-1.73%) | 0.27% | $0 M | Nov 6, 2026 |
| 14 | State Street Corp | 125,473 | 0 (0.00%) | 0.20% | $0 M | Nov 12, 2026 |
| 15 | Northern Trust Corp | 101,129 | 0 (0.00%) | 0.16% | $0 M | Nov 16, 2026 |
| 16 | Spectrum Asset Management, Inc. (NB/CA) | 100,400 | 0 (0.00%) | 0.16% | $0 M | Oct 19, 2026 |
| 17 | Cannon Financial Strategists, Inc. | 92,645 | +19,857 (+27.28%) | 0.15% | $0 M | Oct 19, 2026 |
| 18 | XTX Topco Ltd | 78,914 | +24,640 (+45.40%) | 0.12% | $0 M | Nov 16, 2026 |
| 19 | HRT Financial LP | 62,333 | New | 0.10% | $0 M | Nov 13, 2026 |
| 20 | Morgan Stanley | 57,045 | 0 (0.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 21 | Stifel Financial Corp | 51,000 | 0 (0.00%) | 0.08% | $0 M | Nov 12, 2026 |
| 22 | Advisory Research Inc | 50,000 | 0 (0.00%) | 0.08% | $0 M | Nov 12, 2026 |
| 23 | Raymond James Financial Inc | 40,210 | -94,224 (-70.09%) | 0.06% | $0 M | Nov 12, 2026 |
| 24 | CIBC Bancorp USA Inc. | 20,631 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 25 | Tower Research Capital LLC (TRC) | 19,717 | +15,408 (+357.58%) | 0.03% | $0 M | Nov 16, 2026 |
Show all 39: investors 26 to 39
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Truist Financial Corp | 15,000 | 0 (0.00%) | 0.02% | $0 M | Oct 30, 2026 |
| 27 | Vanguard Global Advisers, LLC | 13,308 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 28 | Farther Finance Advisors, LLC | 12,000 | +6,000 (+100.00%) | 0.02% | $0 M | Oct 8, 2026 |
| 29 | J.W. Cole Advisors, Inc. | 11,000 | 0 (0.00%) | 0.02% | $0 M | Nov 5, 2026 |
| 30 | Commonwealth Equity Services, LLC | 10,723 | 0 (0.00%) | 0.02% | $0 M | Nov 2, 2026 |
| 31 | Two Sigma Securities, LLC | 10,360 | New | 0.02% | $0 M | Nov 16, 2026 |
| 32 | HB Wealth Management, LLC | 10,000 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 33 | Nuveen, LLC | 7,773 | New | 0.01% | $0 M | Nov 10, 2026 |
| 34 | Harbour Investments, Inc. | 5,750 | -3,000 (-34.29%) | 0.01% | $0 M | Nov 9, 2026 |
| 35 | Blue Trust, Inc. | 1,928 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 36 | Larson Financial Group LLC | 1,250 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 37 | Wells Fargo & Company/mn | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 38 | NewEdge Advisors, LLC | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 39 | Osaic Holdings, Inc. | 1,000 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Biotelemetry#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.45 M | $1 M | 2.3% | <0.01% | +92% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 656,120 | $0 M | 1.0% | <0.01% | +100% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 178,950 | $0 M | 0.28% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 155,600 | $0 M | 0.25% | <0.01% | +123% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 47,501 | $0 M | 0.08% | <0.01% | +23% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 44,849 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 32,990 | $0 M | 0.05% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 24,817 | $0 M | 0.04% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,462 | $0 M | 0.02% | <0.01% | +109% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,199 | $0 M | <0.01% | <0.01% | +78% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Biotelemetry#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kenneth Harry PersenChief Technology Officer | Grant or award | +105,740 | — | — | 448,290 | Form 4 |
| filed | Tim CruickshankCFO | Grant or award | +167,760 | — | — | 239,990 | Form 4 |
| filed | Branislav VajdicPresident, Director | Grant or award | +260,870 | — | — | 3.97 M | Form 4 |
| filed | Branislav VajdicPresident, Director | Grant or award | +2.80 M | — | — | 3.71 M | Form 4 |
| filed | Richard FerrariDirector | Buyamended | +57,500 | $0.800 | $46 K | 286,636 | Form 4/A |
| filed | Branislav VajdicDirector | Buy | +31,250 | $0.800 | $25 K | 909,914 | Form 4 |
| filed | Tim CruickshankCFO | Buy | +31,250 | $0.800 | — | 72,230 | Form 4 |
| filed | Richard FerrariDirector | Buy | +62,500 | $0.800 | $50 K | 291,636 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Biotelemetry#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-2.75 reverse split
Trading halts
- 2025-11-21 15:32 UTC, code LUDP, resumed 15:37 UTC
Fails to deliver
- : 41,259 shares at $0.54
- : 135,957 shares at $0.53
- : 17,825 shares at $0.41
- : 311,814 shares at $0.49
- : 12,908 shares at $0.58
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Biotelemetry scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median13.2×Price to book 13.2× against Healthcare's median of 3.1×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-42.7%Free cash flow is -42.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.62 vs -0.73Diluted EPS -0.62 in fiscal 2025 against -0.73 the year before (report's currency).
- ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$1 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-989.2%-989.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.44 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year26.5%Diluted shares up 26.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Biotelemetry: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 13,450+21.7%— | 11,051+62.6%— | 6,798+19.7%— | 5,677+2126%— | 255+91.7%— | 133—— | |
| General and administrative | 7,689−13.0%— | 8,836+3.8%— | 8,516+15.8%— | 7,354+262%— | 2,030+210%— | 655—— | |
| Operating expenses | 21,139+6.3%— | 19,887+29.9%— | 15,314+17.5%— | 13,031+470%— | 2,285+190%— | 788—— | |
| Operating income | −21,139—— | −19,887—— | −15,314—— | −13,031—— | −2,285—— | −788—— | |
| Interest expense and finance costs | — | — | — | — | 2,165+673%— | 280—— | |
| Other non-operating income (expense) | 124−71.8%— | 439−35.0%— | 675+878%— | 69—— | −2,143—— | −280—— | |
| Income before tax | −21,015—— | −19,448—— | −14,639—— | −12,962—— | −4,428—— | −1,068—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −21,015—— | −19,448—— | −14,639—— | −12,962—— | −4,428—— | −1,068—— | |
| Earnings per share, basic | -0.62—— | -0.73—— | -0.72—— | -1.59—— | -1.03—— | -0.29—— | |
| Earnings per share, diluted | -0.62—— | -0.73—— | -0.72—— | -1.59—— | -1.03—— | -0.29—— | |
| Shares, weighted average (basic) | 34+26.5%— | 27+31.0%— | 20+149%— | 8.2+90.6%— | 4.3+17.5%— | 3.6—— | |
| Shares, weighted average (diluted) | 34+26.5%— | 27+31.0%— | 20+149%— | 8.2+90.6%— | 4.3+17.5%— | 3.6—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 4,380+84.3%75.0% | 2,377−85.3%72.6% | 16,189+350%94.5% | 3,594−72.8%89.0% | 13,192+54867%94.2% | 24—47.1% | |
| Inventory | 103—1.8% | 0—0.0% | — | — | — | — | |
| Other current assets | 202−48.6%3.5% | 393−38.2%12.0% | 636+42.9%3.7% | 445−44.8%11.0% | 806+2885%5.8% | 27—52.9% | |
| Current assets | 4,685+69.1%80.2% | 2,770−83.5%84.6% | 16,825+317%98.2% | 4,039—100% | — | — | |
| Property, plant and equipment | 1,102+145%18.9% | 450+75.8%13.7% | 256—1.5% | 0—0.0% | — | — | |
| Total assets | 5,843+78.4%100% | 3,276−80.9%100% | 17,131+324%100% | 4,039−71.1%100% | 13,998+27347%100% | 51—100% | |
| Accounts payable | 1,053+98.3%18.0% | 531−4.5%16.2% | 556r1,194−66.6%3.2% | 1,665+183%41.2% | 588+20.2%4.2% | 489—959% | |
| Current liabilities | 3,240+99.8%55.5% | 1,622+35.8%49.5% | 1,194—7.0% | — | — | 4,836—9482% | |
| Total liabilities | 3,240+99.8%55.5% | 1,622+35.8%49.5% | 1,194−28.3%7.0% | 1,665+183%41.2% | 588−87.8%4.2% | 4,836—9482% | |
| Retained earnings | −77,288—−1323% | −56,273—−1718% | −36,825—−215% | −22,186—−549% | −9,224—−65.9% | −4,796—−9404% | |
| Shareholders' equity | 2,603+57.4%44.5% | 1,654−89.6%50.5% | 15,937+571%93.0% | 2,374−82.3%58.8% | 13,410—95.8% | −4,785—−9382% | |
| Total liabilities and equity | 5,843+78.4%100% | 3,276−80.9%100% | 17,131+324%100% | 4,039−71.1%100% | 13,998+27347%100% | 51—100% | |
| Shares outstanding | 40r27+48.8%— | 27r26+2.4%— | 26+229%— | 8.0+2.6%— | 7.8+121%— | 3.5—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 5,147+19.7%— | 4,299+34.0%— | 3,208+186%— | 1,120+483%— | 192+1820%— | 10—— | |
| Cash from operating activities | −13,988—— | −14,471—— | −12,093—— | −9,948—— | −3,230—— | −600—— | |
| Capital expenditure | −600—— | −201—— | −256—— | 0—— | — | — | |
| Cash from investing activities | −600—— | −201—— | −256—— | 0—— | — | — | |
| Shares issued | — | 730−97.1%— | 24,764+7016%— | 348−97.6%— | 14,713—— | — | |
| Cash from financing activities | 16,591+1816%— | 866−96.5%— | 24,994+7041%— | 350−97.9%— | 16,398+2549%— | 619—— | |
| Change in cash | 2,003—— | −13,806−209%— | 12,645—— | −9,598−173%— | 13,168+69205%— | 19—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 10−21.7%— | 2.1−35.4%— | 2.3−30.0%— | 2.4−32.1%— | 3.4*+16.2%— | 3.3+13.3%— | 3.3+16.9%— | 3.5+43.8%— | 2.9*+43.6%— | 2.9—— | 2.8—— | 2.4—— | 2.0*—— | |
| General and administrative | 8.4+7.9%— | 1.3−33.4%— | 2.8+61.5%— | 2.3+16.6%— | 2.0*−5.0%— | 2.0−7.5%— | 1.7−23.8%— | 2.0−14.6%— | 2.1*−2.0%— | 2.2—— | 2.2—— | 2.4—— | 2.1*—— | |
| Operating expenses | 19−10.6%— | 3.5−34.7%— | 5.1+1.1%— | 4.7−14.3%— | 5.3*+7.4%— | 5.3+4.4%— | 5.0−1.0%— | 5.5+15.1%— | 4.9*+20.3%— | 5.1—— | 5.1—— | 4.8—— | 4.1*—— | |
| Operating income | −19—— | −3.5—— | −5.1—— | −4.7—— | −5.3*—— | −5.3—— | −5.0—— | −5.5—— | −4.9*—— | −5.1—— | −5.1—— | −4.8—— | −4.1*—— | |
| Other non-operating income (expense) | 0.5+238%— | 0.4+1177%— | 0.1−15.9%— | 0.0−20.0%— | 0.0*−78.4%— | 0.0−61.1%— | 0.1−53.0%— | 0.0−88.8%— | 0.0*−83.9%— | 0.1—— | 0.1—— | 0.2—— | 0.2*—— | |
| Income before tax | −18—— | −3.0—— | −5.0—— | −4.7—— | −5.3*—— | −5.3—— | −5.0—— | −5.5—— | −4.9*—— | −5.0—— | −5.0—— | −4.6—— | −3.9*—— | |
| Income tax | 0—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Net income attributable to shareholders | −18—— | −3.0—— | −5.0—— | −4.7—— | −5.3*—— | −5.3—— | −5.0—— | −5.5—— | −4.9*—— | −5.0—— | −5.0—— | −4.6—— | −3.9*—— | |
| Earnings per share, basic | — | -0.05—— | -0.10—— | -0.12—— | — | -0.15—— | -0.15—— | -0.18—— | — | -0.19—— | -0.19—— | -0.17—— | — | |
| Earnings per share, diluted | — | -0.05—— | -0.10—— | -0.12—— | — | -0.15—— | -0.15—— | -0.18—— | — | -0.19—— | -0.19—— | -0.17—— | — | |
| Shares, weighted average (basic) | 57+66.3%— | 57+66.3%— | 53+56.0%— | 41+33.6%— | — | 34+28.6%— | 34+27.4%— | 30+14.6%— | — | 27—— | 27—— | 27—— | — | |
| Shares, weighted average (diluted) | 57+66.3%— | 57+66.3%— | 53+56.0%— | 41+33.6%— | — | 34+28.6%— | 34+27.4%— | 30+14.6%— | — | 27—— | 27—— | 27—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.1—77.0% | 6.1+227%77.0% | 8.7+168%82.0% | 2.0−53.6%51.9% | 4.4+84.3%75.0% | 1.9−67.8%64.5% | 3.3−64.4%54.4% | 4.4−65.3%48.2% | 2.4−85.3%72.6% | 5.8—86.6% | 9.2—90.4% | 13—92.7% | 16—94.5% | |
| Inventory | 0.1—1.4% | 0.1—1.4% | 0.1—1.0% | 0.1—3.4% | 0.1—1.8% | — | — | — | 0—0.0% | — | — | — | — | |
| Other current assets | 0.1—1.5% | 0.1−55.6%1.5% | 0.2−46.8%1.5% | 0.3−42.6%6.7% | 0.2−48.6%3.5% | 0.3−28.2%9.4% | 0.3−43.4%5.1% | 0.5−23.5%5.0% | 0.4−38.2%12.0% | 0.4—5.6% | 0.5—5.4% | 0.6—4.4% | 0.6—3.7% | |
| Current assets | 6.3—80.0% | 6.3+196%80.0% | 9.0+67.8%84.6% | 2.4−71.7%62.0% | 4.7+69.1%80.2% | 2.1−65.4%73.9% | 5.4−44.7%89.6% | 8.6−35.0%94.5% | 2.8−83.5%84.6% | 6.1—92.3% | 9.7—95.8% | 13—97.1% | 17—98.2% | |
| Property, plant and equipment | 1.5—19.3% | 1.5+118%19.3% | 1.6+181%14.9% | 1.4+225%36.6% | 1.1+145%18.9% | 0.7+51.9%24.1% | 0.6+52.4%9.4% | 0.4+28.8%4.9% | 0.5+75.8%13.7% | 0.5—6.9% | 0.4—3.7% | 0.3—2.5% | 0.3—1.5% | |
| Total assets | 7.9—100% | 7.9+174%100% | 11+77.8%100% | 3.9−56.9%100% | 5.8+78.4%100% | 2.9−56.8%100% | 6.0−40.9%100% | 9.1−33.2%100% | 3.3−80.9%100% | 6.7—100% | 10—100% | 14—100% | 17—100% | |
| Accounts payable | 0.3—3.4% | 0.3−73.8%3.4% | 0.6−25.3%5.7% | 0.7+42.8%19.0% | 1.1+98.3%18.0% | 1.0−45.0%35.5% | 0.8−42.7%13.6% | 0.5−52.3%5.7% | 0.5−4.5%16.2% | 1.9—27.9% | 1.4—14.0% | 1.1—8.0% | 0.6r1.2—3.2% | |
| Current liabilities | 1.4—17.3% | 1.4−45.0%17.3% | 2.5+36.7%23.1% | 3.3+109%83.8% | 3.2+99.8%55.5% | 2.5+33.1%85.9% | 1.8+26.7%30.1% | 1.6—17.3% | 1.6+35.8%49.5% | 1.9—27.9% | 1.4—14.0% | — | 1.2—7.0% | |
| Total liabilities | 1.4—17.3% | 1.4−45.0%17.3% | 2.5+36.7%23.1% | 3.3+109%83.8% | 3.2+99.8%55.5% | 2.5+33.1%85.9% | 1.8+26.7%30.1% | 1.6+43.8%17.3% | 1.6+35.8%49.5% | 1.9—27.9% | 1.4—14.0% | 1.1—8.0% | 1.2—7.0% | |
| Retained earnings | −90—−1144% | −90—−1144% | −87—−818% | −82—−2087% | −77—−1323% | −72—−2503% | −67—−1116% | −62—−678% | −56—−1718% | −51—−772% | −46—−458% | −41—−304% | −37—−215% | |
| Shareholders' equity | 6.5—82.7% | 6.5+1504%82.7% | 8.2+95.5%76.9% | 0.6−91.6%16.2% | 2.6+57.4%44.5% | 0.4−91.5%14.1% | 4.2−52.0%69.9% | 7.5−40.0%82.7% | 1.7−89.6%50.5% | 4.8—72.1% | 8.7—86.0% | 13—92.0% | 16—93.0% | |
| Total liabilities and equity | 7.9—100% | 7.9+174%100% | 11+77.8%100% | 3.9−56.9%100% | 5.8+78.4%100% | 2.9−56.8%100% | 6.0−40.9%100% | 9.1−33.2%100% | 3.3−80.9%100% | 6.7—100% | 10—100% | 14—100% | 17—100% | |
| Shares outstanding | 58—— | 58+67.5%— | 56+65.6%— | 41+21.9%— | 40r27+48.8%— | 34+29.1%— | 34+28.1%— | 34+28.1%— | 27r26+2.4%— | 27—— | 27—— | 26—— | 26—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2,641+1.1%— | 937−34.6%— | 1,701+44.5%— | 1.2+9.7%— | 1.4*+42.8%— | 1,433+36.1%— | 1,177r1.2+113073%— | 1.1−8.1%— | 1.0*−15.8%— | 1,053r1.1—— | 1.0—— | 1.2—— | 1.2*—— | |
| Cash from operating activities | −12—— | −2.6*—— | −3.3*—— | −3.6—— | −2.9*—— | −3.2*—— | −3.4*—— | −4.5—— | −4.2*—— | −3.3*—— | −3.6*—— | −3.5—— | −2.9*—— | |
| Capital expenditure | −1.0—— | −0.1*—— | −0.2*—— | −0.2—— | −0.4*—— | −0.1*—— | −0.1*—— | 0—— | 0*—— | −0.1*—— | −0.0*—— | −0.1—— | −0.1*—— | |
| Cash from investing activities | −1.0—— | −0.1*−104%— | −0.2*−113%— | −0.2—— | −0.4*—— | 1.7*—— | 1.9*—— | −3.8—— | 0*—— | −0.1*—— | −0.0*—— | −0.1—— | −0.1*—— | |
| Shares issued | — | — | — | — | — | — | — | 10—— | 0.7*—— | 0*—— | 0.1*—— | 0—— | 0*—— | |
| Cash from financing activities | 18+53.3%— | 0*−100%— | 10*+2183%— | 1.5−85.2%— | 5.8*+668%— | 0.0*+114%— | 0.5*+436%— | 10—— | 0.8*—— | 0.0*—— | 0.1*—— | 0—— | 0*—— | |
| Change in cash | 4.2—— | −2.7*—— | 6.7*—— | −2.3−216%— | 2.5*—— | −1.4*—— | −1.1*—— | 2.0—— | −3.4*—— | −3.4*—— | −3.5*—— | −3.6—— | −3.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Biotelemetry#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Directors and officers 9 · Material agreement 4 · Agreement ended 1 · Shareholder vote 4
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Directors and officers | 8-K/A | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026
H-1B hiring at Biotelemetry#
3 labor condition applications certified in fiscal 2025 for 3 positions, at a median wage of $229 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director of Platform ITComputer and Information Systems Managers | 1 | $229 K |
| Sr. Software EngineerSoftware Developers | 1 | $144 K |
| Vice President, Software EngineeringComputer and Information Systems Managers | 1 | $245 K |
Where: South Jordan, UT 1 · Brea, CA 1 · Foothill Ranch, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 3 | 3 | $229 K | 3 |
| FY2024 | 1 | 1 | $220 K | 1 |
| FY2023 | 1 | 1 | $103 K | 1 |
| FY2022 | 1 | 1 | $217 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as HeartBeam, Inc.
How Biotelemetry compares in Healthcare
- Market cap$34 M · higher than 17% of 2,013
- Price / book13.2× · lower than 10% of 1,245
- FCF yield-42.7% · higher than 20% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Biotelemetry🇺🇸 | $34 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Biotelemetry? Verify and update this profile — free
Show Biotelemetry's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.